Forbes Institute for Cancer Discovery

Max Wicha, MD

The end of cancer begins here

The Forbes Institute for Cancer Discovery empowers scientists across U-M to pursue high-risk, high-reward projects with the potential to advance research from the laboratory to the clinic. By providing bold, cross-departmental funding opportunities, we are fueling new and innovative approaches to prevention, early diagnosis, and treatment of cancer.

Founded by Sidney and Madeline Forbes, long-time Detroit-area philanthropists, the institute was launched in 2016 with a particular focus on translating the most promising laboratory research into new therapies that benefit patients. Led by Max Wicha, MD, it is a vital part of the Rogel Cancer Center’s research enterprise, providing game-changing grants to faculty to propel research toward cures.

Innovation. Discovery. Entrepreneurship. This is the way we are going to save lives.

Our Mission

Aggressively advance scientific discoveries to clinical applications that better prevent, treat, and cure cancer.

Our Vision

  • Catalyze scientific innovation, business, and philanthropy
  • Empower physicians, engineers, chemists, computer scientists, mathematicians, physicists, and others across campus to pursue high-risk, high-reward cancer research
  • Leapfrog lag time between new concepts, discovery, and optimization
  • Overcome the funding gap for translational research (while we are consistently among the leaders in research funding from the National Cancer Institute, only a small fraction of grants awarded by the National Cancer Institute support translational research)
  • Leverage the breadth and depth of expertise at U-M, which is unmatched by freestanding cancer centers
Unveiling the Forbes Institute for Cancer Discovery

Impact Reports
  • 2023 Report
  • 2022 Report
  • 2021 Report
  • 2020 Report
  • 2019 Report
  • 2018 Report

    • Support the Forbes Institute for Cancer Discovery

    Through grants funded entirely by philanthropy, we are creating bridges from oncology to critical care medicine, pathology, public health, math, chemistry, engineering, and more. We are bringing all disciplines to bear on advancing new cancer therapies.

    Make a Gift

    Meet our Director

    Max Wicha, MD

    Max S Wicha, MD
    Madeline and Sidney Forbes Professor of Oncology and Professor of Internal Medicine
    Medical School

    About the Forbes Family
    forbes-institute-group-photo

    Longtime Detroit-area philanthropists and dedicated friends of the University of Michigan, Madeline and Sidney Forbes of Bloomfield Hills, Mich., launched the Forbes Institute for Cancer Discovery in June 2016. They are proud Wolverine parents and grandparents who generously support Michigan Medicine, the Department of Athletics, and the U-M Museum of Art.

    Sidney founded the Forbes Company in 1996 and has worked to create landmark properties and redefine the parameters of commercial development. The Forbes Company portfolio includes the Somerset Collection in Troy, Mich., and several distinctive centers throughout Florida. The family’s distinguished history of philanthropy in the Detroit area includes generous support for the arts, medical research, and education. Sidney is a director emeritus of the Detroit Symphony Orchestra and honorary director of the Detroit Institute of the Arts. Madeline is a trustee of the Jewish Women’s Foundation of Metropolitan Detroit.

    Nathan “Nate” Forbes is the managing partner of the Forbes Company. He represents the family’s dedication to high-impact research on the Rogel Cancer Center’s National Advisory Board. He and his wife, Catherine, served on the Leadership Committee for U-M’s historic Victors for Michigan campaign, which raised more than $5 billion to support students, faculty, capital expansion, and the pursuit of bold ideas.

    News & Stories
    lab tests purple tops
    Health Lab

    Blood-based multi-cancer screening tests: Ready for primetime?

    Blood-based multi-cancer screening tests may hold promise, but U-M experts recommend proven cancer screening methods and genetic risk assessment first.
         microbes inside gut yellow
    Health Lab

    New oral nanomedicine boosts effectiveness of cancer immunotherapies

    University of Michigan researchers developed an oral drug that can increase the ability of T cells to attack tumors. The drug uses the microbial metabolite 3,4-dihydroxybenzoic acid, which is derived from dietary fiber.
         Microscope images of prostate cancer cells
    Health Lab

    New drug combination may help treat advanced prostate cancer

    University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.
         presentation on stage with slideshow up
    Health Lab

    Medical students develop novel technological solutions for unmet patient needs

    University of Michigan medical students showcased AI-driven healthcare innovation projects focused on melanoma support, transplant recovery and primary care access.
         cancer cell floating with yellow dots drawn out blue
    Health Lab

    Biomarkers aid cost-benefit analysis of head and neck cancer immunotherapy

    The cost-effectiveness of the immunotherapy drug pembrolizumab for patients with locally advanced head and neck squamous cell carcinoma may depend on biomarker results, according to a new study by Michigan Medicine.
         close up of cells blue purple pink
    Health Lab

    Researchers create new path to target hard-to-drug prostate cancer protein

    University of Michigan researchers have identified a specific pocket within ERG, a driver of prostate cancer, and have developed a small molecule probe, called PBITE-1, that can bind to it.